# SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

> **NCT06538935** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- SBRT
- Immune Checkpoint Blockade
- Tyrosine Kinase Inhibitor

## Interventions

- **DRUG:** adbelimumab
- **PROCEDURE:** SBRT
- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT06538935
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538935, "SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06538935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*